Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT04449874
PHASE1

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation

Sponsor: Genentech, Inc.

View on ClinicalTrials.gov

Summary

This is a Phase I dose-escalation and dose-expansion study that will evaluate the safety, pharmacokinetics (PK), and preliminary activity of GDC-6036 in patients with advanced or metastatic solid tumors with a KRAS G12C mutation.

Official title: A Phase Ia/Ib Dose-Escalation and Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-6036 as a Single Agent and in Combination With Other Anti-cancer Therapies in Patients With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

498

Start Date

2020-07-29

Completion Date

2027-12-31

Last Updated

2026-02-12

Healthy Volunteers

No

Interventions

DRUG

GDC-6036

The starting dose of GDC-6036 in the combination Arms B, C, D, E, F and G will be determined from Stage I Arm A (single-agent dose escalation).

DRUG

Atezolizumab

A 1200 milligram (mg) intravenous (IV) infusion of atezolizumab will be administered on Day 1 of 21 day cycles.

DRUG

Cetuximab

Cetuximab will be administered at an initial dose of 400 milligram per square meter (mg/m\^2) IV infusion followed by 250 mg/m\^2 IV infusion weekly in 21 day cycles.

DRUG

Bevacizumab

A 15 milligram per kilogram (mg/kg) IV infusion of bevacizumab will be administered on Day 1 of 21 day cycles.

DRUG

Erlotinib

150 mg of erlotinib will be administered PO QD in 21 day cycles.

DRUG

GDC-1971

The starting dose of GDC-1971 will be determined from its single-agent dose escalation.

DRUG

Inavolisib

The starting dose of inavolisib will be determined from its single-agent dose escalation.

Locations (63)

City of Hope Comprehensive Cancer Center

Duarte, California, United States

UCSD Moores Cancer Center

La Jolla, California, United States

Chao Family Comprehensive Cancer Center UCI

Orange, California, United States

Yale Cancer Center

New Haven, Connecticut, United States

Dana Farber Cancer Institute

Boston, Massachusetts, United States

University of Oklahoma

Oklahoma City, Oklahoma, United States

Abramson Cancer Center

Philadelphia, Pennsylvania, United States

UPMC - Hillman Cancer Center

Pittsburgh, Pennsylvania, United States

St Vincent's Hospital Sydney

Darlinghurst, New South Wales, Australia

Slade Health Inward goods

Mount Kuring-Gai, New South Wales, Australia

Peter MacCallum Cancer Center

Melbourne, Victoria, Australia

Alfred Health

Melbourne, Victoria, Australia

Linear Clinical Research Limited

Nedlands, Western Australia, Australia

UZ Antwerpen

Edegem, Belgium

CHU de Liège

Liège, Belgium

AZ St Maarten Campus Leopoldstr

Mechelen, Belgium

Santa Casa de Misericordia de Belo Horizonte - PPDS

Belo Horizonte, Minas Gerais, Brazil

Hospital Erasto Gaertner

Curitiba, Paraná, Brazil

Hospital de Clinicas de Porto Alegre HCPA PPDS

Pôrto Alegre, Pará, Brazil

Universidade de Caxias do Sul

Caxias do Sul, Rio Grande do Sul, Brazil

Hospital Sao Lucas Da Pontificia Universidade Catolica Do Rio Grande Do Sul (PUCRS)

Porto Alegre, Rio Grande do Sul, Brazil

Instituto Nacional de Câncer

Rio de Janeiro, Brazil

Ottawa Hospital

Ottawa, Ontario, Canada

Princess Margaret Cancer Centre

Toronto, Ontario, Canada

Jewish General Hospital

Montreal, Quebec, Canada

Clinexpert Gyongyos Kft

Gyöngyös, Hungary

Rambam Medical Center

Haifa, Israel

Sheba Medical Center - PPDS

Ramat Gan, Israel

Tel-Aviv Sourasky Medical Center

Tel Aviv, Israel

Istituto Scientifico Romagnolo Per Lo Studio E La Cura Dei Tumori IRST - PPDS

Meldola, Emilia-Romagna, Italy

Irccs Ospedale San Raffaele

Milan, Lombardy, Italy

Asst Grande Ospedale Metropolitano Niguarda

Milan, Lombardy, Italy

Istituto Clinico Humanitas

Rozzano (MI), Lombardy, Italy

Azienda Ospedaliero Universitaria Pisana

Pisa, Tuscany, Italy

The Aga Khan University-Kenya.

Nairobi, Kenya

Het Nederlands Kanker Instituut Antoni Van Leeuwenhoek Ziekenhuis

Amsterdam, Netherlands

Leids Universitair Medisch Centrum

Leiden, Netherlands

Maastricht University Medical Center

Maastricht, Netherlands

Universitair Medisch Centrum Utrecht

Utrecht, Netherlands

Auckland City Hospital, Cancer and Blood Research

Auckland, New Zealand

Auckland City Hospital

Auckland, New Zealand

New Zealand Clinical Research - Christchurch

Christchurch, New Zealand

Haukeland University Hospital

Bergen, Norway

Oslo university hospital Radiumhospitalet

Oslo, Norway

Uniwersyteckie Centrum Kliniczne, O?rodek Bada? Klinicznych Wczesnych Faz

Gdansk, Poland

Biokinetica, Przychodnia Jozefow

Józefów, Poland

Seoul National University Bundang Hospital

Seongnam-si, South Korea

Seoul National University Hospital

Seoul, South Korea

Asan Medical Center - PPDS

Seoul, South Korea

Samsung Medical Center - PPDS

Seoul, South Korea

Hospital Universitari Vall d'Hebron

Barcelona, Spain

START Madrid-FJD, Hospital Fundacion Jimenez Diaz

Madrid, Spain

Hospital Universitario 12 de Octubre

Madrid, Spain

Hospital Universitario HM Sanchinarro-CIOCC

Madrid, Spain

Hospital Clinico Universitario Virgen de la Victoria

Málaga, Spain

Hospital Universitario Virgen del Rocío

Seville, Spain

Hospital Clinico Universitario de Valencia

Valencia, Spain

Inselspital

Bern, Switzerland

Hôpitaux Universitaires de Genève

Geneva, Switzerland

Queen Elizabeth Hospital

Birmingham, United Kingdom

Velindre Cancer Centre

Cardiff, United Kingdom

University College London Hospitals NHS Foundation Trust

London, United Kingdom

The Christie NHS Foundation Trust

Manchester, United Kingdom